On January 19, 2023 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that it will be presenting at the upcoming Virtual Investor Summit on January 26, 2023 (Press release, Soligenix, JAN 19, 2023, View Source [SID1234626395]). The presentation will take place at 9:00 AM ET. To view the presentation, please visit View Source The Company was one of 25 companies selected to attend this conference based on its key catalysts, including the submission of a new drug application for its lead product candidate, HyBryte, in the treatment of cutaneous T-cell lymphoma. For more information about the Investor Summit, please refer to their website at View Source The conference is complimentary to qualified investors, and registration is available via the conference website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key members of Soligenix management will hold one-on-one meetings during the conference. If you are unable to attend the conference and would like to schedule a meeting with management separately, please contact [email protected].